Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results
Select data models

Selected data models

You must log in to select data models for download or further analysis.

5 Search results.

Rotterdem Symptom Checklist (RSCL) Week 36 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 36

- 7/15/17 - 1 form, 1 itemgroup, 2 items, 1 language

Itemgroup: Symptom checklist

Study part: Rotterdem Symptom Checklist (RSCL) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 38 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 38

- 6/5/17 - 1 form, 1 itemgroup, 2 items, 1 language

Itemgroup: Symptom checklist

Study part: Rotterdem Symptom Checklist (RSCL) Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 24 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 24

- 6/5/17 - 1 form, 1 itemgroup, 2 items, 1 language

Itemgroup: Symptom checklist

Study part: Rotterdem Symptom Checklist (RSCL) Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 12 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 12

- 6/5/17 - 1 form, 1 itemgroup, 2 items, 1 language

Itemgroup: Symptom checklist

Study part: Rotterdem Symptom Checklist (RSCL) Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Day 1 Pre-Infusion

- 6/5/17 - 1 form, 1 itemgroup, 2 items, 1 language

Itemgroup: Symptom checklist

Study part: Rotterdem Symptom Checklist (RSCL) Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.